Coherus Oncology, Inc. (CHRS)
1.07
+0.02
(+1.90%)
USD |
NASDAQ |
Oct 15, 16:00
1.07
0.00 (0.00%)
After-Hours: 20:00
Coherus Oncology Cash from Operations (TTM) : -186.03M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -186.03M |
| March 31, 2026 | -170.57M |
| December 31, 2025 | -138.51M |
| September 30, 2025 | -90.19M |
| June 30, 2025 | -105.87M |
| March 31, 2025 | 0.50M |
| December 31, 2024 | -20.44M |
| September 30, 2024 | -61.98M |
| June 30, 2024 | -54.27M |
| March 31, 2024 | -152.92M |
| December 31, 2023 | -174.88M |
| September 30, 2023 | -261.90M |
| June 30, 2023 | -244.69M |
| March 31, 2023 | -255.81M |
| December 31, 2022 | -241.12M |
| September 30, 2022 | -193.49M |
| June 30, 2022 | -142.69M |
| March 31, 2022 | -92.84M |
| December 31, 2021 | -37.43M |
| September 30, 2021 | 48.01M |
| June 30, 2021 | 81.66M |
| March 31, 2021 | 142.04M |
| December 31, 2020 | 154.14M |
| September 30, 2020 | 138.73M |
| Date | Value |
|---|---|
| June 30, 2020 | 146.33M |
| March 31, 2020 | 98.82M |
| December 31, 2019 | 28.36M |
| September 30, 2019 | -36.72M |
| June 30, 2019 | -134.46M |
| March 31, 2019 | -182.66M |
| December 31, 2018 | -159.27M |
| September 30, 2018 | -141.82M |
| June 30, 2018 | -140.55M |
| March 31, 2018 | -160.59M |
| December 31, 2017 | -200.29M |
| September 30, 2017 | -257.26M |
| June 30, 2017 | -277.69M |
| March 31, 2017 | -249.51M |
| December 31, 2016 | -252.54M |
| September 30, 2016 | -160.09M |
| June 30, 2016 | -157.79M |
| March 31, 2016 | -151.24M |
| December 31, 2015 | -107.99M |
| September 30, 2015 | -146.84M |
| June 30, 2015 | -92.36M |
| March 31, 2015 | -71.73M |
| December 31, 2014 | -23.93M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Enanta Pharmaceuticals, Inc. | -35.32M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Anika Therapeutics, Inc. | 5.977M |
| Savara, Inc. | -110.38M |